Diagnostic imaging company RadNet (NASDAQ: RDNT) met Wall Street’s revenue expectations in Q3 2026, with sales up 22.1% year on year to $638.3 million. Its non-GAAP profit of $0.30 per share was 35.5% above analysts’ consensus estimates.

Is now the time to buy RDNT? Find out in our full research report (it’s free for active Edge members).

StockStory’s take

RadNet’s third quarter results were well received, with management attributing revenue and margin expansion to strong demand for advanced imaging services and operational improvements across its imaging centers. CEO Howard Berger highlighted the impact of investments in new PET/CT and MRI technology, increased capacity utilization, and a favorable shift toward higher-margin procedures. The expansion of joint ventures with health systems and robust growth in the Digital Health segment also contributed, with Berger noting that “cost-effective, freestanding outpatient imaging centers are essential to [health systems’] long-term strategies.”

Looking ahead, RadNet’s outlook centers on further growth in advanced imaging and digital health, supported by ongoing capacity expansion and integration of AI-powered solutions. Management expects the pending ONRAD acquisition to enhance its ability to serve hospitals with teleradiology and radiology staffing, while also accelerating the deployment of AI tools across both outpatient and hospital settings. CFO Mark Stolper emphasized that “rolling into 2027 with $140+ million worth of annual recurring revenue in Digital Health” will be a key driver, while COO Sham Sokka underscored that automating radiologist workflows is expected to improve productivity and cost efficiency.

Key insights from management’s remarks

Management credited broad-based procedure growth, product launches, and joint venture expansion as primary drivers, while also highlighting the Digital Health segment’s progress and the strategic ONRAD acquisition.

• Advanced imaging demand: RadNet saw strong growth in MRI, CT, and PET/CT volumes, attributed to broader industry trends and investments in faster equipment and workflow technology. CEO Howard Berger pointed to increased PET/CT capacity enabled by new scanners, which reduced procedure times and doubled throughput compared to two years ago.
• Capacity and operational initiatives: The company’s TechLive remote technologist platform now covers 13% of MRI exams, helping offset staffing shortages and maximizing equipment utilization. Management also expanded hours at key centers and accelerated new center openings beyond initial plans.
• Digital Health momentum: The Digital Health segment achieved a record quarter for new business, with over $71 million in contract value and 67% growth in annual recurring revenue (ARR) year-over-year. President Kees Wesdorp noted a growing customer base and successful integration of the Gleamer acquisition, driving both product and geographic expansion.
• AI-enabled workflow efficiency: Deployment of AI-powered reporting and automation tools has reached over 30% of RadNet exams, with a path to full deployment by early next year. COO Sham Sokka highlighted that over 90% of AI-generated draft reports for thyroid ultrasound required no edits, reducing radiologist workload and reporting time.
• ONRAD acquisition progress: The acquisition of ONRAD positions RadNet to offer end-to-end imaging solutions for hospitals, addressing radiologist shortages and expanding professional services. Management expects ONRAD’s high-margin, capital-light model to be immediately accretive, with integration of AI tools anticipated to further enhance operational efficiency and service offerings.

Drivers of future performance

Management expects continued growth in advanced imaging, expanded digital health adoption, and ONRAD integration to underpin next year’s results, while monitoring reimbursement risk and operational investments.

• Advanced imaging and center growth: RadNet anticipates ongoing demand for advanced imaging procedures, with capacity expansion supported by new equipment, longer operating hours, and additional center openings. Management views increased throughput as the most profitable growth lever, particularly as more procedures are shifted to outpatient settings.
• Digital Health and AI deployment: The company’s Digital Health segment is expected to drive recurring revenue growth through new customer contracts, SaaS conversions, and full-scale rollout of AI-powered workflow tools. Management highlighted that automating radiologist tasks could boost productivity by up to 50%, supporting both margin improvement and differentiation from competitors.
• Integration and reimbursement risk: ONRAD’s integration is projected to expand RadNet’s hospital presence and enable cross-selling of digital solutions, but management acknowledged that Medicare reimbursement cuts and regulatory changes remain a headwind. CFO Mark Stolper noted that while current estimates show a limited revenue impact, potential legislative changes could affect the final outcome.

Catalysts in upcoming quarters

In the coming quarters, our team will be monitoring (1) the pace of advanced imaging volume growth and capacity utilization, (2) the integration and performance of the ONRAD acquisition, and (3) the continued expansion and monetization of the Digital Health segment’s AI and workflow solutions. We will also track developments in Medicare reimbursement and the rollout of digital registration tools across RadNet centers.

RadNet currently trades at $78.34, up from $76 just before the earnings. In the wake of this quarter, is it a buy or sell? See for yourself in our full research report (it’s free).

High quality stocks for all market conditions

ONE MORE THING: Top 6 Stocks for This Week. This market is separating quality stocks from expensive ones fast. AI is taking down whole sectors with no warning. In a rotation this fast, you need more than a list of good companies.

Our AI system flagged Palantir before it ran 1,662% between October 2022 and February 2026. AppLovin before it ran 753% between February 2024 and February 2026. Nvidia before it ran 1,178% between January 2023 and February 2026. Each week it produces 6 new names that pass the same tests. Get Our Top 6 Stocks for Free HERE.

Stocks that have made our list include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+1,154% between June 2020 and June 2025). Find your next big winner with StockStory today.